Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

ClinicalTrials.gov ID: NCT02531035

Public ClinicalTrials.gov record NCT02531035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).

Study identification

NCT ID
NCT02531035
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lexicon Pharmaceuticals
Industry
Enrollment
1,405 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2015 (Actual)
Primary completion
Apr 2017 (Actual)
Completion
Apr 2017 (Actual)
Last update posted
Feb 12, 2020

2015 – 2017

United States locations

U.S. sites
33
U.S. states
19
U.S. cities
33
Facility City State ZIP Site status
Lexicon Investigational Site Concord California 94520 —
Lexicon Investigational Site Escondido California 92025 —
Lexicon Investigational Site La Jolla California 92037 —
Lexicon Investigational Site San Marcos California 94401 —
Lexicon Investigational Site Ventura California 93003 —
Lexicon Investigational Site Walnut Creek California 94598 —
Lexicon Investigational Site Aurora Colorado 80045 —
Lexicon Investigational Site New Haven Connecticut 06511 —
Lexicon Investigational Site Orlando Florida 32804 —
Lexicon Investigational Site West Palm Beach Florida 33401 —
Lexicon Investigational Site Atlanta Georgia 30318 —
Lexicon Investigational Site Macon Georgia 31210 —
Lexicon Investigational Site Roswell Georgia 30076 —
Lexicon Investigational Site New Orleans Louisiana 70112 —
Lexicon Investigational Site Rockville Maryland 20852 —
Lexicon Investigational Site Boston Massachusetts 02215 —
Lexicon Investigational Site Bloomfield Hills Michigan 48302 —
Lexicon Investigational Site Omaha Nebraska 68114 —
Lexicon Investigational Site Las Vegas Nevada 89148 —
Lexicon Investigational Site Albany New York 12206 —
Lexicon Investigational Site The Bronx New York 10467 —
Lexicon Investigational Site Asheville North Carolina 28803 —
Lexicon Investigational Site Chapel Hill North Carolina 27517 —
Lexicon Investigational Site Greenville North Carolina 27834 —
Lexicon Investigational Site Morehead City North Carolina 28557 —
Lexicon Investigational Site Grand Forks North Dakota 58201 —
Lexicon Investigational Site Bend Oregon 97701 —
Lexicon Investigational Site Sioux Falls South Dakota 57104 —
Lexicon Investigational Site Austin Texas 78731 —
Lexicon Investigational Site San Antonio Texas 78229 —
Lexicon Investigational Site Shavano Park Texas 78231 —
Lexicon Investigational Site Salt Lake City Utah 84107 —
Lexicon Investigational Site Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02531035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2020 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02531035 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →